1. Generics Bulletin
  2. >>Market Intelligence
  3. >>Company Rankings

The Generics Bulletin Top 50, Part Two: Mid-Table Firms Move Up And Down

As Certain Companies Ascend, Others Are Moving In The Opposite Direction

 
• By Dave Wallace

In the second part of Generics Bulletin’s Top 50, we look at the mid-table players and how they have shifted positions this year.

Generics Bulletin Top 50 2023
Ups and downs have been seen in the middle of our ranking • Source: Shutterstock

With two new spaces having opened up in our rundown of the top 10 generics and biosimilars companies this year – allowing Dr Reddy’s and Cipla to ascend out of the middle table covering positions 11-30 in our ranking, and into the top 10 (see sidebar) – this has left room for further firms to climb up the charts in the second part of the Generics Bulletin Top 50.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Company Rankings

More from Market Intelligence